Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
Tempus AI (TEM) is back in focus after investors linked a major melanoma trial milestone to its pending US$1.5b acquisition of Personalis Inc, raising fresh questions about how this cancer data deal fits the stock’s story.
See our latest analysis for Tempus AI.
At a latest share price of US$72.69, Tempus AI has seen strong short term momentum, with a 30 day share price return of 54.79% and a 90 day share price return of 57.41%. However, the 1 year total shareholder return is down 9.72%, suggesting the recent melanoma trial news and Personalis acquisition have sharply shifted sentiment after a weaker first year.
If this kind of move has your attention, it could be worth scanning for other healthcare AI stocks showing strong trends and solid fundamentals through the 41 healthcare AI stocks
Bulls see Tempus AI as a rare way to gain exposure to cancer data at scale, while bears point to ongoing losses and a sharp premium after the recent surge. Which side does the current valuation favor?
Most Popular Narrative: 10.3% Overvalued
Tempus AI last closed at $72.69 while the most followed narrative places fair value at $65.90. That gap sets the stage for a very different story to the current melanoma buzz.
The market has also become more reasonable on valuation.
After the recent pullback, the stock trades around 5.7x forward revenue while the underlying business is still expected to grow organically by roughly 25% in 2026.
According to QuanD, the narrative leans heavily on a compound mix of revenue growth, margin lift and a future profit multiple usually reserved for mature software leaders. Curious which specific assumptions pull the fair value below today’s price and how they stack against Tempus AI’s current losses and rapid data expansion.
Result: Fair Value of $65.90 (OVERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, there are clear pressure points, including ongoing net losses of $254.425m and the risk that Tempus AI’s high growth assumptions or premium multiples prove too optimistic.
Find out about the key risks to this Tempus AI narrative.
Another View: Tempus AI Versus Cash Flow Valuation
The first narrative pegs Tempus AI at around 10.3% overvalued using growth and profit multiples, yet the SWS DCF model points the other way. At a share price of $72.69, Tempus AI is trading 33.1% below an estimated future cash flow value of $108.63, which screens as undervalued.
That gap between a multiple based fair value of $65.90 and a DCF fair value above $100 leaves investors weighing which set of assumptions feels more realistic for Tempus AI. Is the market overpaying for sales today or underpaying for potential future cash flows?
Look into how the SWS DCF model arrives at its fair value.
TEM Discounted Cash Flow as at Aug 2026
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Tempus AI for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.
Next Steps
Does the split sentiment around Tempus AI leave you undecided yet interested? If so, move quickly, review the key data points and weigh both sides with the 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Tempus AI?
Do not stop with Tempus AI. Use the Simply Wall St Screener to quickly surface fresh stock ideas that match your risk tolerance and income goals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include TEM.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com